Marksans Pharma Profile
Key Indicators
- Authorised Capital ₹ 69.00 Cr
- Paid Up Capital ₹ 45.32 Cr
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 226.00 Cr
- Satisfied Charges ₹ 337.16 Cr
- Revenue Growth 2.16%
- Profit Growth -1.08%
- Ebitda -19.18%
- Net Worth 41.63%
- Total Assets 39.28%
About Marksans Pharma
Marksans Pharma Limited (MPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 16 April 1992 and has a history of 32 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524404 and on the National Stock Exchange(NSE) under MARKSANS.
The Corporate was formerly known as Tasc Industries (India) Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 69.00 Cr and a paid-up capital of Rs 45.32 Cr.
The company currently has active open charges totaling ₹226.00 Cr. The company has closed loans amounting to ₹337.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Marksans Pharma Limited India are Harshavardhan Panigrahi as COMPANY SECRETARY and Jitendra Sharma as Cfo. Abhinna Sundar, Sandra Saldanha, Digant Parikh, and Five other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
Industry
What products or services does Marksans Pharma Limited offer?
Marksans Pharma Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Immunomodulator Drugs, Sexual Wellness Products, Fertility Enhancer, Cardiovascular Drugs & Medication, Diabetes Medicine, Cardiac Drugs, Common Disease Medicines, IV Fluids.
Who are the key members and board of directors at Marksans Pharma?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Harshavardhan Panigrahi ![]() | Company Secretary | 16-Feb-2009 | Current |
Jitendra Sharma ![]() | CFO | 12-Aug-2014 | Current |
Mark Saldanha ![]() | Managing Director | 06-Oct-2015 | Current |
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Digant Parikh ![]() | Director | 14-Mar-2018 | Current |
Abhinna Sundar ![]() | Director | 11-Jul-2019 | Current |
Sandra Saldanha ![]() | Whole-Time Director | 25-Sep-2014 | Current |
Sunny Sharma ![]() | Director | 11-Aug-2021 | Current |
Seetharama Buddharaju ![]() | Director | 05-Oct-2011 | Current |
Varddhman Jain ![]() | Whole-Time Director | 24-Jan-2019 | Current |
Financial Performance of Marksans Pharma.
Marksans Pharma Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.16% increase. The company also saw a slight decrease in profitability, with a 1.08% decrease in profit. The company's net worth Soared by an impressive increase of 41.63%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Marksans Pharma?
In 2023, Marksans Pharma had a promoter holding of 43.85% and a public holding of 56.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹226.00 Cr
₹337.16 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 226.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
07 Feb 2006 | State Bank Of India | ₹226.00 Cr | Open |
07 Sep 2017 | State Bank Of India | ₹66.80 Cr | Satisfied |
23 Jun 2015 | State Bank Of India | ₹44.41 Cr | Satisfied |
23 Dec 2013 | Bank Of India | ₹4.00 Cr | Satisfied |
13 Aug 2010 | Bank Of India | ₹6.00 Cr | Satisfied |
How Many Employees Work at Marksans Pharma?
Marksans Pharma has a workforce of 95 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Marksans Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marksans Pharma's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.